Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 14/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 9/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780688 | 0.85 | JAK2 (0.50) | MAPK1MAPK3JAK2JAK1KDM4E | |
| SCHEMBL7979377 | 0.84 | MAPK1 (0.50) | MAPK1MAPK3JAK2JAK1PARP1 | |
| SCHEMBL16125525 | 0.84 | MAPK1 (0.58) | MAPK1MAPK3FLT3KDM4EALDH1A1 | |
| SCHEMBL20217228 | 0.83 | MAPK1 (0.77) | MAPK1MAPK3TTKALDH1A1 | |
| SCHEMBL4403122 | 0.81 | MAPK1 (0.43) | MAPK1MAPK3JAK2JAK1KDM4E | |
| SCHEMBL10325224 | 0.79 | SCN9A (0.45) | MAPK1MAPK3JAK2JAK1 | |
| SCHEMBL1145076 | 0.79 | MAP2K4 (0.57) | MAPK1MAPK3JAK2JAK1KDM4E | |
| SCHEMBL16308650 | 0.79 | KIF11 (0.50) | MAPK1MAPK3JAK2JAK1KDM4E | |
| SCHEMBL31504557 | 0.79 | MAP2K4 (0.57) | MAPK1MAPK3JAK2JAK1KDM4E | |
| SCHEMBL13387169 | 0.78 | DYRK1A (0.46) | MAPK1JAK2JAK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | MAPK1 467/4885MAPK3 744/4885JAK2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.